AMENDMENTS TO THE CLAIMS:

This Listing of Claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1. (Currently amended) A method for ~~immunostimulation in~~ stimulating an immune response in a mammal having a pathogen or tumour ~~in need of immunostimulation~~, comprising the following steps:

(a) administering to the mammal at least one mRNA ~~containing a region~~ which codes for at least one antigen of a pathogen or codes for at least one tumour antigen and

(b) separately administering to the mammal at least one ~~cytokine~~ mRNA which codes for GM-CSF~~,~~

~~whereby an immune response in the mammal is intensified or modulated~~.

2. (Previously Presented) The method according to claim 1, wherein step (b) is carried out 1 minute to 48 hours after step (a).

3. (Previously Presented) The method according to claim 1, wherein in step (a) at least one RNase inhibitor is additionally administered.

4. (Currently Amended) [[A]] The method according to claim 1, wherein the modulation of the immune response comprises a modification from a Th2 immune response into a Th1 immune response in said mammal.

5. (Currently amended) The method according to claim 1, wherein the at least one mRNA from step (a) ~~contains a region which~~ codes for at least one antigen from a tumour selected from the group consisting of: 707-AP, AFP, ART-4, BAGE, β-catenine/m, Bcr-abl, CAMEL, CAP-1, CASP-8, CDC27/m, CDK4/m, CEA, CMV pp65, CT, Cyp-B,

DAM, EGFRl, ELF2M, ETV6-AMLl, G250, GAGE, GnT-V, Gpl00, HAGE, HBS, HER-2/neu, HLA-A*020l-R170I, HPV-E7, HSP70-2M, HAST-2, hTERT (or hTRT), influenza matrix protein, [[or]] influenza A matrix Ml protein, [[or]] influenza B matrix Ml protein, iCE, KIAA0205, LAGE, [[e.g.]] LAGE-l, LDLR/FUT, MAGE, [[e.g.]] MAGE-A, MAGE-B, MAGE-C, MAGE-A1, MAGE-2, MAGE-3, MAGE-6, MAGE-10, MART-l/melan-A, MClR, myosine/m, MUCl, MUM-1, -2, -3, NA88-A, NY-ESO-l, p190 minor bcr-abl, Pml/RARα, PRAME, proteinase 3, PSA, PSM, PTPRZl, RAGE, RUI or RU2, SAGE, SART-l or SART-3, SEC6lG, SOX9, SPCl, SSX, survivin, TEL/AML1, TERT, TNC, TPI/m, TRP-l, TRP-2, TRP-2/INT2, tyrosinase and WT1.

6. (Cancelled).

7. (Previously Presented) The method according to claim 1, wherein the at least one mRNA from step (a) and/or from step (b) is complexed or condensed with at least one cationic or polycationic agent.

8. (Currently Amended) The method according to claim 1, wherein the at least one mRNA from step (a) and/or from step (b) is ~~in the form of~~ globin UTR (untranslated regions)-stabilized mRNA.

9. (Currently Amended) The method according to claim 1, wherein the at least one mRNA from step (a) and/or from step (b) is ~~in the form of~~ modified mRNA.

10. (Previously Presented) The method according to claim 9, wherein the *G/C* content of the coding region of the modified mRNA from step (a) and/or from step (b) is increased compared with the G/C content of the coding region of the corresponding wild-type mRNA.

11. (Currently Amended) The method according to claim 9, wherein the modified

mRNA includes a ribosome binding site and the A/U content in the environment of the ribosome binding site of the modified mRNA from step (a) and/or from step (b) is increased compared with the A/U content in the environment of the ribosome binding site of the wild-type mRNA.

12. (Previously Presented) The method according to claim 9, wherein the coding region and/or the 5' and/or 3' untranslated region of the modified mRNA from step (a) and/or from step (b) is modified compared with the wild-type mRNA such that it contains no destabilizing sequence elements.

13. (Previously Presented) The method according to claim 9, wherein the modified mRNA from step (a) and/or from step (b) has a 5' cap structure and/or a poly(A) tail and/or at least one 5' and/or 3' stabilizing sequence.

14. (Previously Presented) The method according to claim 9, wherein the modified mRNA from step (a) and/or from step (b) contains at least one analogue of naturally occurring nucleotides.

15. (Previously Presented) The method according to claim 9, wherein the modified mRNA from step (a) and/or from step (b) is complexed or condensed with at least one cationic or polycationic agent.

16. (Previously Presented) The method according to claim 15, wherein the cationic or polycationic agent is selected from the group consisting of protamine, poly-L-lysine, poly-L-arginine and histones.

17. (Currently amended) The method according to claim 1, wherein the ~~immunostimulation is carried out in connection with treatment of tumour diseases, allergies, autoimmune diseases, and~~ pathogen is a protozoological, viral and/or bacterial infections ~~in a mammal in need in immunostimulation~~.

18. - 20. Cancelled

21. (Previously Presented) The method according to claim 7, wherein the cationic or polycationic agent is selected from the group consisting of protamine, poly-L-lysine, poly-L-arginine and histones.

22. (New) The method of claim 1 wherein step (b) is carried out 20 minutes to 36 hours after step (a).

23. (New) The method of claim 1 wherein step (b) is carried out 10 hours to 30 hours after step (a).

24. (New) The method of claim 1 wherein step (b) is carried out 12 hours to 28 hours after step (a).

25. (New) The method of claim 1 wherein step (b) is carried out 20 hours to 26 hours after step (a).

26. (New) The method of claim 1 wherein step (b) is carried out 24 hours after step (a).

27. (New) The method of claim 1 wherein the immune response is a Th1 response.